Innocoll Holdings Names Fante as Chief Executive Officer
7 March 2019 - - Ireland-based specialty pharmaceutical company Innocoll Holdings Ltd. has named Richard Fante as chief executive officer and as a member of Inncoll's board of directors, the company said.

Fante, who currently serves as Innocoll's chief commercial officer and head of business development, succeeds Anthony Zook, who retired from his role as Innocoll CEO.

Fante joined Innocoll in 2015 as chief commercial officer and head of business development.

In this role, he built an experienced, highly talented commercial team to prepare the company for commercialisation and also led all business development activities, including Innocoll's acquisition by Gurnet Point.

Prior to Innocoll, Fante spent nearly twenty years at AstraZeneca in the United States, serving in a variety of leadership roles, including president, US, CEO of North America and Regional vice president of the Americas.

He also formerly served as an independent director for Inhibikase Therapeutics, Inc. Fante graduated from Princeton University with a B.A. in Biology and received an MBA from the University of North Carolina at Chapel Hill.

Innocoll is a specialty pharmaceutical company focused on the development and commercialisation of pharmaceutical technologies Its current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.

Gurnet Point Capital is a healthcare fund founded by Ernesto Bertarelli and led by Chris Viehbacher, who.